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Of the four tenascins found in bony fish and tetrapods, tenascin-W is the least
understood. It was first discovered in the zebrafish and later in mouse, where it was
mistakenly named tenascin-N. Tenascin-W is expressed primarily in developing and
mature bone, in a subset of stem cell niches, and in the stroma of many solid tumors.
Phylogenetic studies show that it is the most recent tenascin to evolve, appearing first in
bony fishes. Its expression in bone and the timing of its evolutionary appearance should
direct future studies to its role in bone formation, in stem cell niches, and in the treatment
and detection of cancer.
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Tenascins are a family of extracellular matrix glycoproteins with a distinctive domain architecture (1).
There are four family members: tenascin-C, tenascin-R, tenascin-X, and tenascin-W. All monomeric
tenascins share a similar N-terminus comprised of heptad repeats flanked by cysteine residues. One or
more epidermal growth factor (EGF)-like repeats are present near N-terminus, followed by variable
numbers of fibronectin-type III (FNIII) domains. At the C-terminus is a large fibrinogen-related
domain. Most tenascins form trimers via coiled-coil interactions within their N-terminal
oligomerization domain, and some (tenascin-C and tenascin-W) can form hexamers through
cysteine cross bridges. The original tenascin, and the best studied member of the family, is
tenascin-C (1). The C in tenascin-C stands for cytotactin, which was one of the early names used
for this protein. The second tenascin to be discovered was originally named restrictin since its
expression is largely “restricted” to the nervous system.When it became clear that restrictin was closely
related to tenascin-C, it was renamed tenascin-R. Tenascin-X received its name because it was encoded
by the unknown “gene X”, which partly overlaps the human CYP21B gene. The domain architecture of
tenascin-X is highly variable in different taxonomic groups, so its homolog in the chicken was initially
named tenascin-Y until its true identity was discovered by phylogenetic analysis (2). The fourth and
final member of the tenascin gene family is tenascin-W, which is the topic of this perspective article.THE DISCOVERY AND EXPRESSION OF TENASCIN-W
In the decades prior to genomic sequencing, many researchers attempted to discover novel
members of a gene family of interest by low-stringency hybridization screening of cDNAorg February 2021 | Volume 11 | Article 6233051
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conserved between members within the family. This approach
was used by Philipp Weber and colleagues (3) to obtain the first
tenascin-W sequence. In their study, a zebrafish cDNA library
was screened for tenascin-related molecules using a radioactively
labeled 444-bp sequence probe encoding the EGF repeats of rat
tenascin-R. The 4 positive clones with sequences related to
tenascins were amplified, subcloned and sequenced, and the
missing 5’ sequence was determined by rapid amplification.
While the experimental design seemed more likely to result in
the cloning of tenascin-R from zebrafish, the resulting sequence
appeared novel based on low sequence homologies with known
tenascins. Weber and colleagues chose the name tenascin-W,
presumably after the name of the discoverer. The cDNA
sequence revealed a tenascin-type domain structure: an N-
terminal signal peptide, a cysteine-rich domain likely to permit
oligomerization, three EGF-like repeats, five FNIII domains, and
a C-terminal fibrinogen-related domain.
The presence of a novel tenascin in zebrafish led to a race to
find its mammalian homologue. The first of two papers describing
the discovery of murine tenascin-W was published by John
Neidhardt and colleagues (4). This group used BLAST to screen
mouse expressed sequence tags (ESTs) for novel sequences
encoding EGF repeats and FNIII domains, and found two
overlapping sequences that did not correspond to the known
sequences of murine tenascin-C and tenascin-R. The complete
coding sequence was then found using rapid amplification and
RT-PCR, revealing a tenascin with three EGF-like repeats, 12
FNIII domains and a C-terminal fibrinogen-related domain.
Phylogenetic relationships between their novel tenascin and
known tenascins placed the new murine tenascin in the
tenascin-W clade. However, since it had 12 FNIII domains and
not five as reported in zebrafish, they concluded that they had
found a new tenascin and named it tenascin-N after the paper’s
first author. The authors noted that many of the FNIII domains
were very similar to each other, so much so that the amino acid
sequences 6th and 8th FNIII domains were identical. They also
reported that tenascin-N mRNA was abundant in brain, kidney
and spleen, and less so in the developing embryo than in the adult
mouse. The authors confirmed protein expression in the brain by
immunohistochemistry.
The second paper describing tenascin-W in the mouse (5),
submitted prior to the appearance of the paper by Neidhardt
et al. (4), described the cloning of the homologue using PCR
primers based on a human EST reported to be “similar to
tenascin-R” (accession number AL049689). Overlapping
cDNAs were assembled into a presumptive full-length coding
sequence encoding 3 EGF-like repeats, 9 FNIII domains and a
fibrinogen-related domain. The authors concluded that they
found the murine homologue of tenascin-W as both the
domain organization and sequence were most similar to
zebrafish tenascin-W. They also noted that the similar FNIII
domains (domains 3–8) corresponded to the 3rd and 4th FNIII
domains of zebrafish tenascin-W, and they hypothesized that
murine tenascin-W was larger than zebrafish tenascin-W due to
the repetitive duplication of these domains over time.Frontiers in Immunology | www.frontiersin.org 2Immunohistochemistry revealed tenascin-W in developing
smooth muscle and periosteum, in certain stem cell niches, as
well as in the adult kidney. They did not report expression in the
developing or adult central nervous system.
Why did the authors of these papers come to such different
conclusions? We now know that the number of repeats or
domains found in tenascins are very poor predictors of
homology (1). Human tenascin-C has up to 17 FNIII domains,
whereas its homologue in zebrafish (NP_570982) has nine. The
human tenascin-X gene encodes 32 FNIII domains, whereas
tenascin-X in some bony fish has only three. The numbers of
EGF-like repeats are more similar across species, but even those
repeats are highly variable in number in tenascin-X (2). The
variable numbers of FNIII domains in tenascin-W (five in
zebrafish and 12 in mouse) is likely to be the result of a
duplication of the 3rd FNIII domain, which is encoded on a
single exon (2). In the pufferfish tenascin-W has only four FNIII
domains, but the 3rd domain duplicated twice in the zebrafish to
give it six potential FNIII domains, one more than was
sequenced by Weber et al. (3). Three copies of this domain are
found in chicken tenascin-W, six in human, and nine in
mouse. An exposed loop in this domain contains a potential
integrin binding site, but this has yet to be demonstrated
experimentally (2).
Phylogenetic tree construction is a more reliable way to identify
homologues. When the fibrinogen-related domains of tenascins
(the single large domain is easier to align than multiple—and
variable—smaller domains) from zebrafish, chicken, mouse and
human are used to establish their relationships using the
phylogenetic tree-making program NGPhylogeny.fr (5), the
mouse “tenascin-N” sequence clearly falls in the tenascin-W
clade (Figure 1A). Similar results have been published by others
(see below).
To date, the only evidence of tenascin-W expression in the
central nervous system comes from Neidhardt et al. (4). Others
found that the primary sites of expression are developing palate,
bone and smooth muscle, certain stem cell niches, and in adult
kidney, spleen, and periosteum (7–12). The absence of significant
tenascin-W expression in brain parenchyme was confirmed by
the tissue-based map of the human proteome published by
Uhlén at el. (13).
Tenascin-W is also highly expressed in solid tumors (14–18).
Details of tenascin-W expression in cancer can be found in a
recent review (19).
How is tenascin-W expression regulated? Most of the work
published to date on this subject has been done using C2C12 cells,
or preosteoblast or osteo-chondroprogenitors, and these studies
indicate that BMP-2 can upregulate tenascin-W expression, either
directly or indirectly, through a p38-dependent signaling pathway
(12, 14, 20). TNF-alpha can upregulate tenascin-W in mouse
embryo fibroblasts (14), and Wnt3a, Wnt5a, and shear stress can
upregulate tenascin-W expression in pre-osteoblastic MCT3T3-
E1 cells (12). The regulation by Wnts is p38 dependent, but
regulation by shear stress is JNK dependent. Tenascin-W
expression accompanies osteoblastic differentiation in primary
cultures (9), in Kusa-A1 cells (21) and in C2C12 cells (7), but notFebruary 2021 | Volume 11 | Article 623305
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expression dramatically decreases during osteogenic
differentiation (12), and addition of exogenous tenascin-W to
MCT3T3-E1 cells can inhibit their differentiation as well (20).THE EVOLUTION OF TENASCIN-W
Tenascins are relatively modern additions to the extracellular
matrix. Tenascins or tenascin-like proteins are limited to the
Phylum Chordata (2, 6, 22, 23), suggesting that tenascins co-
evolved with a dorsal hollow nerve cord and pharyngeal
apparatus. In amphioxus and tunicates there are single
tenascin genes, and phylogenetic trees constructed using the
sequences of the fibrinogen-related domains do not place these
tenascins from invertebrate chordates in any particular clade.
Two tenascins are found in the lamprey, and in cartilaginous fish
(the elephant shark Callorhinchus milii) there are three: tenascin-
C, tenascin-R, and tenascin-X (6). Tenascin-W is present in all
Euteleostomi (i.e., all chordates with bones). Since that report,
the genomes of the thorny skate Amblyraja radiata and the
whale shark Rhincodon typus have been reported. As with the
elephant shark, these cartilaginous fish have tenascin-C
(XM_033049212.1; XM_020527269.1) and tenascin-R
(XM_033029137.1; XM_020515183.1), but they do not appear
to have a tenascin-W.
Did tenascin-W evolve from tenascin-C or tenascin-R?
Phylogenetic trees based on the amino acid sequences of the
fibrinogen-related domains from bony chordates have been
inconclusive (6). The addition of the skate and whale shark
sequences to the analysis does suggest a closer, but still tenuous,Frontiers in Immunology | www.frontiersin.org 3relationship to tenascin-R of ancient Actinopterygii
Erpetoichthys calabaricus (the reedfish) and the ancient teleost
arowana Scleropages formosus (Figure 1B). The best evidence of
the origin of tenascin-W is the observation that in all genomes
examined tenascin-W is found adjacent to tenascin-R encoded in
the opposite orientation (2). For example, in the zebrafish
tenascin-W and tenascin-R are found adjacent to each other
on chromosome 2, with tenascin-W on the negative strand and
tenascin-R on the positive strand. In the mouse, these genes are
adjacent to each other on chromosome 1, and once again
tenascin-W is on the negative strand and tenascin-R is on the
positive strand. This indicates that tenascin-W likely evolved
from an isolated reverse tandem duplication event, and not from
whole genome duplication. The latter probably resulted in the
duplication of tenascin-X in the zebrafish, as tenascin-XB
(XP_021323869.1) is on chromosome 19 and tenascin-XBA
(XP_02132258.1) is on chromosome 16; chromosomes 19 and
16 in the zebrafish share a large number of paralogous genes (24).
Interestingly, many of the genes that were duplicated in zebrafish
by tandem duplication events have been linked to immune
pathways (24).FUTURE DIRECTIONS
Unlike tenascin-C, we still know very little about the basic
biology of tenascin-W. It is typically abundant in solid tumors
and can affect cancer cell behavior (19), but the significance of
these observations is still unknown. It is possible that tenascin-W
plays a role similar to tenascin-C in the creation of an immune-
suppressive environment in tumor stroma (25), though thisA B
FIGURE 1 | (A) A dendrogram constructed using the fibrinogen-related domain amino acid sequences of zebrafish, chicken, mouse and human tenascins. The tree
was constructed using the default tools and parameters at NGPhylogeny.fr (5). The murine tenascin-W (TNW), originally named tenascin-N (TNN), segregates to the
TNW clade. (B) A phylogenetic tree constructed using the fibrinogen-related domain amino-acid sequences of tenascin-C (TNC) and tenascin-R (TNR) from the
cartilaginous thorny skate and whale shark, as well as the ancient bony reedfish and arowana, and from the fibrinogen-related domains of reedfish and arowana
tenascin-X (TNX) and TNW. The tree was constructed using the same parameters as Adams et al. (6) and branch support is indicated. TNW co-evolved with the
bony fishes, most likely from a duplication of the TNR gene. See text for details.February 2021 | Volume 11 | Article 623305
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tenascin-W, like that of tenascin-C, can bind and activate TLR4,
which indicates tenascin-W may play a role in inflammation and
inflammatory diseases (26). In addition, its prominent
expression in the periosteum, a dense connective tissue around
the bones containing progenitor cells that develop into
osteoblasts, and at sites of osteogenesis, suggests a role for
tenascin-W in bone repair and remodeling. The stimulating
effect of tenascin-W on osteoblastic progenitors’ differentiation
and migration (9) seems to confirm this hypothesis, but contrary
observations have also been published (20). It is likely that future
studies of the role of tenascin-W in bone will not only clarify the
role for this extracellular matrix in normal bone development
and remodeling, but also after bone injury and in diseases. Such a
function of tenascin-W remains to be demonstrated in animal
models of bone fracture repair and of osteoporosis. The highly
specific expression of tenascin-W in other (non-osteogenic) stem
cell niches, like in the corneal limbus or cuspid niche of the aortic
valve, strongly suggests a role in tissue homeostasis and repair
after injury, which still requires experimental confirmation.
The authors of this perspective would also like to encourage
those who study tenascin-W to use that name instead of
tenascin-N, or at least include both in their descriptions. It
seems more appropriate to recognize the original discover of
the protein in zebrafish than to use the name that was attributed,Frontiers in Immunology | www.frontiersin.org 4incorrectly, by one of the first to find this protein in mouse
almost 5 years later.DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in
the article/supplementary material. Further inquiries can be
directed to the corresponding author.AUTHOR CONTRIBUTIONS
Each author (MD, AS, and RT) contributed to the conception,
writing, and/or final editing of this paper. All authors
contributed to the article and approved the submitted version.ACKNOWLEDGMENTS
The authors would like to acknowledge the critical roles played
by our late friend, colleague, and mentor, Ruth Chiquet-
Ehrismann, in the discovery and study of tenascins.REFERENCES
1. Chiquet-Ehrismann R, Tucker RP. Tenascins and the importance of adhesion
modulation. Cold Spring Harb Perspect Biol (2011) 3. doi: 10.1101/
cshperspect.a004960
2. Tucker RP, Drabikowski K, Hess JF, Ferralli J, Chiquet-Ehrismann R,
Adams JC. Phylogenetic analysis of the tenascin gene family: evidence of
origin early in the chordate lineage. BMC Evol Biol (2006) 6:60. doi: 10.1186/
1471-2148-6-60
3. Weber P, Montag D, Schachner M, Bernhardt RR. Zebrafish tenascin-W, a
new member of the tenascin family. J Neurobiol (1998) 35:1–16.
4. Neidhardt J, Fehr S, Kutsche M, Löhler J, Schachner M. Tenascin-N:
characterization of a novel member of the tenascin family that mediates
neurite repulsion from hippocampal explants. Mol Cell Neurosci (2003)
23:193–209. doi: 10.1016/s1044-7431(03)00012-5
5. Lemoine F, Correia D, Lefort V, Doppelt-Azerloual O, Mareuil F, Cohen-
Boulakia S, et al. NGPhylogeny.fr: new generation phylogenetic services for
non-specialists. Nucleic Acids Res (2019) 47(W1):W260–5. doi: 10.1093/nar/
gkz303
6. Adams JC, Chiquet-Ehrismann R, Tucker RP. The evolution of tenascins and
fibronectin. Cell Adh Migr (2015) 9:22–33. doi: 10.4161/19336918.2014.970030
7. Scherberich A, Tucker RP, Samandari E, Brown-Luedi M, Martin D, Chiquet-
Ehrismann R. Murine tenascin-W: a novel mammalian tenascin expressed in
kidney and at sites of bone and smooth muscle development. J Cell Sci (2004)
117:571–81. doi: 10.1242/jcs.00867
8. Meloty-Kapella CV, Degen M, Chiquet-Ehrismann R, Tucker RP. Avian
tenascin-W: expression in smooth muscle and bone, and effects on calvarial
cell spreading and adhesion in vitro. Dev Dyn (2006) 235:1532–42.
doi: 10.1002/dvdy.20731
9. Meloty-Kapella CV, Degen M, Chiquet-Ehrismann R, Tucker RP. Effects of
tenascin-W on osteoblasts in vitro. Cell Tissue Res (2008) 334:445–55.
doi: 10.1007/s00441-008-0715-4
10. Tucker RP, Ferralli J, Schittny JC, Chiquet-Ehrismann R. Tenascin-C and
tenascin-W in whisker follicle stem cell niches: possible roles in regulating
stem cell proliferation and migration. J Cell Sci (2013) 126:5111–15.
doi: 10.1242/jcs.13465011. Tucker RP, Peterson CA, Hendaoui I, Bichet S, Chiquet-Ehrismann R. The
expression of tenascin-C and tenascin-W in human ossicles. J Anat (2016)
229:416–21. doi: 10.1111/joa.12496
12. Morgan JM, Wong A, Yellowley CE, Genetos DC. Regulation of tenascin
expression in bone. J Cell Biochem (2011) 112:3354–63. doi: 10.1002/jcb.23265
13. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A,
et al. Proteomics. Tissue-based map of the human proteome. Science (2015)
347:6220. doi: 10.1126/science.1260419
14. Scherberich A, Tucker RP, Degen M, Brown-Luedi M, Andres AC, Chiquet-
Ehrismann R. Tenascin-W is found in malignant mammary tumors, promotes
alpha8 integrin-dependent motility and requires p38MAPK activity for BMP-
2 and TNF-alpha induced expression in vitro. Oncogene (2005) 24:1525–32.
doi: 10.1038/sj.onc.1208342
15. Degen M, Brellier F, Kain R, Ruiz C, Terracciano L, Orend G, et al. Tenascin-
W is a novel marker for activated tumor stroma in low-grade human breast
cancer and influences cell behavior. Cancer Res (2007) 67:9169–79. doi:
10.1158/0008-5472.CAN-07-0666
16. Degen M, Brellier F, Schenk S, Driscoll R, Zaman K, Stupp R, et al. Tenascin-
W, a new marker of cancer stroma, is elevated in sera of colon and breast
cancer patients. Int J Cancer (2008) 122:2454–61. doi: 10.1002/ijc.23417
17. Martina E, Degen M, Ruegg C, Merlo A, Lino MM, Chiquet-Ehrismann R,
et al. Tenascin-W is a specific marker of glioma-associated blood vessels and
stimulates angiogenesis in vitro. FASEB J (2010) 24:778–87. doi: 10.1096/fj.09-
140491
18. Brellier F, Martina E, Degen M, Heuze-Vourc’h N, Petit A, Kryza T, et al.
Tenascin-W is a better cancer biomarker than tenascin-C for most human
solid tumors. BMC Clin Pathol (2012) 12:14. doi: 10.1186/1472-6890-12-14
19. Tucker RP, Degen M. The expression and possible functions of tenascin-W
during development and disease. Front Cell Dev Biol (2019) 7:53. doi: 10.3389/
fcell.2019.00053
20. Kimura H, Akiyama H, Nakamura T, de Crombrugghe B. Tenascin-W
inhibits proliferation and differentiation of preosteoblasts during
endochondral bone formation. Biochem Biophys Res Commun (2007)
356:935–41. doi: 10.1016/j.bbrc.2007.03.071
21. Mikura A, Okuhara S, Saito M, Ota M, Ueda K, Iseki S. Association of
tenascin-W expression with mineralization in mouse calvarial development.February 2021 | Volume 11 | Article 623305
Degen et al. Tenascin-WCongenit Anom (Kyoto) (2009) 49:77–84. doi: 10.1111/j.1741-4520.2009.
00227.x
22. Tucker RP, Chiquet-Ehrismann R. Evidence for the evolution of tenascin and
fibronectin early in the chordate lineage. Int J Biochem Cell Biol (2009)
41:424–34. doi: 10.1016/j.biocel.2008.08.003
23. Özbek S, Balasubramanian PG, Chiquet-Ehrismann R, Tucker RP, Adams JC.
The evolution of extracellular matrix. Mol Biol Cell (2010) 21:4300–5.
doi: 10.1091/mbc.E10-03-0251
24. Howe K, Clark MD, Torroja CF, Torrance J, Berthelot C, Muffato M, et al. The
zebrafish reference genome sequence and its relationship to the human
genome. Nature (2013) 496:498–503. doi: 10.1038/nature12111
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